LC/MS-Based Global Metabolomic Identification of Serum Biomarkers Differentiating Hepatocellular Carcinoma from Chronic Hepatitis B and Liver Cirrhosis
Hong Pan, Qing Wu, Qiao qiao Yin, Yi N. Dai, Yi Huang, Wei Zheng, Tian Hui, Mei J. Chen, Ming S. Wang, Jia J. Zhang, Hai Huang, Yong X. Tong
Abstract
-eicosapentaenoic acid, and glycyrrhizic acid had a diagnosis performance with liver disease progression. These four metabolites have a significant correlation with alpha fetal protein (AFP) level and age. Our results highlight novel metabolic biomarkers that have the potential to be used for differentiating between CHB, LC, and HCC patients, thereby facilitating the identification and treatment of patients with early-stage HCC.
Topics & Concepts
Hepatocellular carcinomaCirrhosisMetabolomicsMedicineInternal medicineGastroenterologyMetaboliteMetabolomeStage (stratigraphy)BioinformaticsBiologyPaleontologyMetabolomics and Mass Spectrometry StudiesLiver Disease Diagnosis and TreatmentCancer, Hypoxia, and Metabolism